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1 SUMMARY 
 
3´,4´-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) is a new designer drug 
of the pyrrolidinophenone-type. This substance of abuse is used as a stimulating and 
performance-enhancing drug with similar effects than methylenedioxypyrovalerone 
(MDPV) or cocaine. MDPBP appeared on the worldwide drugs of abuse market during 
the last years and was seized in Germany for the first time in 2009. This drug can be 
purchased on the Internet as so called ‘bath salt’, ‘plant fertilizer’ or ‘NRG-1’.  
The aim of the presented work was to study the phase I and phase II metabolism of 
MDPBP in rat urine and by single enzyme preparations. Therefore, rat urine samples 
were extracted with and without enzymatic hydrolysis and were derivatized afterwards. 
Metabolites were then separated and identified by gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MSn). All in 
all, 17 phase I and 7 phase II metabolites could be identified. The phase I steps were: 
demethylenation of the methylenedioxy moiety and methylation to the corresponding 
demethylenyl-methyl compounds, oxidative deamination to the corresponding 
2´-oxo compounds, hydroxylation of the butyl side chain and oxidation to the 
corresponding ketone, hydroxylation of the phenyl ring, hydroxylation of the 2´-position 
of the pyrrolidine ring followed by dehydrogenation to the corresponding lactams, 
hydroxylation of the 2´-position of the pyrrolidine ring followed by ring opening to the 
respective aliphatic aldehyde and further oxidation to the carboxylic acid, degradation of 
the pyrrolidine ring to the corresponding primary amines and reduction of the keto group 
to the corresponding secondary alcohols. As phase II reactions, glucuronidation, 
methylation and sulfation were observed. The Cytochrome P450 (CYP) isoenzymes 
involved in the main metabolic step could be identified as CYP2C19 and CYP2D6. 
Additionally, CYP2D6 could be identified as the isoenzyme responsible for the main part 
of the total MDPBP CYP-dependent clearance.  
The presented metabolism study demonstrated the extensive metabolism of MDPBP by 
the rat. Due to the enormous increase of new designer drugs and the corresponding 
health risks, it is an important issue to identify and to study new emerged substances. 
The presented study could therefore contribute to identification and detection of MDPBP 
by elucidating its metabolic pathways. Supposing similar kinetic processes in rats and 
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humans, this study could serve as a basis for developing suitable screening strategies 
for detection of a MDPBP intake. 
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2 ZUSAMMENFASSUNG 
 
3´,4´-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) ist eine neue 
Designerdroge vom Pyrrolidinophenon-Typ. Diese Droge findet Verwendung als 
Aufputschmittel oder wird zur Leistungsförderung missbraucht und hat ähnliche 
Wirkungen wie Methylenedioxy-pyrovalerone (MDPV) oder Kokain. MDPBP zählt zu 
den Neuerscheinungen der letzten Jahre auf dem weltweiten Dogenmarkt und wurde 
erstmals 2009 in Deutschland beschlagnahmt. Die Substanz kann im Internet erworben 
werden als sognannte „Badesalze“, „Pflanzendünger“ oder als „NRG-1“, welches oft 
eine Mixtur mit verschiedenen Cathinon-Derivaten ist.  
Ziel dieser Studie ist die Identifizierung der Phase I und Phase II Stoffwechselprodukte 
von MDPBP in Rattenurin und mittels Enzym Experimenten. Die Aufarbeitung des 
Rattenurins erfolgte sowohl mit, als auch ohne Konjugatspaltung und anschließender 
Derivatisierung. Die Separation und Identifizierung der Metaboliten erfolgte unter 
Verwendung von Gaschromatographie-Massenspektrometrie (GC-MS) und 
Flüssigchromatographie-Massenspektrometrie (LC-MSn). Nach entsprechender 
Probenvorbereitung und Versuchsdurchführung wurden 17 Phase I und 7 Phase II 
Metaboliten identifiziert. Die nachgewiesenen Phase I Stoffwechselwege waren 
folgende: Demethylenierung der Methylendioxybrücke und anschließende Methylierung 
zur korrespondierenden DemethylenylMethyl-Verbindung, oxidative Deaminierung zur 
2´-oxo-Verbindung, Hydroxylierung der Butyl-Seitenkette und nachfolgende Oxidation 
zum entsprechenden Keton, Hydroxylierung des Phenylrings, Hydroxylierung der 
2´-Position des Pyrrolidinrings gefolgt von Dehydrogenierung zum Laktam, 
Hydroxylierung der 2´-Position des Pyrrolidinrings mit anschließender Ringöffnung zum 
korrespondierenden Aldehyd und ferner Oxidation zur Carbonsäure, Dealkylierung zum 
primären Amin und Reduktion der Keto-Gruppe zum entsprechenden sekundären 
Alkohol. Als Phase II Reaktionen konnten Glucuronidierungen, Methylierungen und 
Sulfatierungen beobachtet werden. Des Weiteren konnte gezeigt werden, dass die 
Cytochrome P450 Isoenzyme CYP2D6 und CYP2C19 für die Hauptstoffwechselwege 
von MDPBP verantwortlich sind. Davon wiederum übernimmt CYP2D6 den größten Teil 
der CYP-abhängigen Metabolisierung von MDPBP.  
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Zusammenfassend lässt sich sagen, dass anhand dieser Studie nachgewiesen werden 
konnte, dass MDPBP von Ratten ausgiebig verstoffwechselt wird. Aufgrund der 
Tatsache, dass es zurzeit zu einem enormen Anstieg neuer Designerdrogen auf dem 
illegalen Drogenmarkt kommt und den damit einhergehenden gesundheitlichen Risiken, 
ist es von erheblicher Wichtigkeit diese zu identifizieren und deren Metabolismus zu 
studieren. Diese Arbeit konnte hierzu ihren Beitrag leisten, indem der Metabolismus von 
MDPBP aufgeklärt wurde und diese Droge somit mittels des Stoffwechselweges 
identifiziert und detektiert werden kann. In Annahme, dass die Kinetik im menschlichen 
Körper, derer in Ratten ähnelt, kann diese Doktorarbeit als Basis dienen, um eine 
MDPBP Einnahme detektieren zu können. 
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3 INTRODUCTION 
 
3.1 Designer Drugs of the Pyrrolidinophenone-Type 
 
After alpha-pyrrolidinophenone (PPP),[1, 2] 4´-methyl-alpha-pyrrolidinopropiophenone 
(MPPP),[1, 3] 4´-methyl-alpha-pyrrolidinohexanophenone (MPHP),[4] 4´-methoxy-alpha-
pyrrolidinopropiophenone (MOPPP),[5] 3´4´-methylenedioxy-alpha-pyrrolidinopropio-
phenone (MDPPP),[6] 4´-methyl-alpha-pyrrolidinobutyrophenone (MPBP),[7] alpha-
pyrrolidinovalerophenone (PVP),[8] and methylenedioxy-pyrovalerone (MDPV),[9] 
4´-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) was the latest of the 
pyrrolidinophenones, which appeared on the illicit drug market in Germany. Their 
chemical structures are given in Fig. 1. So far MDPPP (1997), PPP (1998),            
MPPP (1999), and MDPV (2012) have been scheduled in the German Controlled 
Substances Act and their possession is prohibited.[8] 
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Figure 1: Chemical structures of pyrrolidinophenone-type designer drugs and of the 
psychostimulant pyrovalerone. 
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In Germany, MDPBP was first seized as a white powder mixed with lactose during a 
traffic control in 2009. Later analysis showed that the substance occurred in form of its 
hydrochloride (HCl).[10] MDPBP can be purchased via the Internet on different online 
shops as so called ‘legal high’, declared for example as ‘bath salt’, ‘plant fertilizer’ or 
‘NRG-1’, which is a mixture with other drugs (Fig. 2). Due to the fact that these drugs of 
abuse are pharmacologically and toxicologically untested, the mode of action and 
adverse reactions could not be described in detail. Hence, only little information about 
application, dosage, pharmacological and toxicological effects of MDPBP is available so 
far. It is supposed to be taken nasally or orally like other pyrrolidinophenones, which 
have been distributed among drug abusers as powders, tablets or capsules.[11] 
 
 
http://mcnewsreport.blogspot.de/2011/05/bath-salts-devil-is-in-details.html 
Figure 2: Example for ‘NRG-1’ and so called ‘bath salts’ sold on the Internet. 
 
Because of its close structural relation to pyrovalerone (Fig. 1), which was the first 
commercially available drug from the large group of alpha-pyrrolidinovalerophenones, it 
can be expected that application, dosage, pharmacological, and toxicological effects are 
similar. Pyrovalerone is a psychostimulant drug, which was synthesized and appeared 
on the market in the 1960s.[12-14] The mode of action of this drug is the release of 
dopamine and norepinephrine from the respective nerve terminals.[15, 16] This mode of 
action was first studied in animal experiments by Stille et al. in the early 1960s.[17] These 
authors compared pyrovalerone with amphetamine and reported that pyrovalerone had 
similar central stimulatory effects as amphetamine, but in contrast, less influence on 
locomotor activity and autonomous functions. The oral median lethal dose (LD50 value) 
of this substance in mice was reported to be 350 mg per kg body mass. Additionally, 
controlled human studies showed similar results.[13, 18] Further studies on pyrovalerone 
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analogues, concerning their biological activity on different transporters in 2006, revealed 
that these substances are inhibitors of dopamine and norepinephrine transporters with 
little effects on serotonin transport.[19] Furthermore, pyrovalerone was tested as a 
therapeutic drug for symptomatic therapy of chronic fatigue or lethargy.[12] But the abuse 
of intravenous drug use made it necessary to withdraw this substance from the 
market.[20] 
 
 
3.2 Metabolism of Pyrrolidinophenones 
 
Metabolism studies on novel drugs of abuse are important for clinical and forensic 
toxicology, workplace drug testing or doping control as prerequisite for thorough 
screening procedures. Concerning the fast moving development of new designer drugs, 
analytical data, such as clarifying drug metabolites and main metabolic steps, are 
essential to identify new emerging compounds. In case of PPP, MPPP, MPHP, MPBP, 
MOPPP, MDPPP, PVP and MDPV, the qualitative metabolism has been studied in 
animals, whereas in case of pyrovalerone metabolism studies have been performed in 
animals and also in human beings. So far, no data about the metabolites and main 
metabolic steps of MDPBP are available. 
However, urine is used as biological sample for screening and identification of drugs or 
poisons, because it is easier available than other body fluids and usually contains a 
higher concentration of metabolites or the drug itself. Powerful methods for the 
identification of metabolites are GC-MS and LC-MSn. They allow the simultaneous 
detection of many toxicants in biosamples in only one single step. Individual compounds 
can be identified by comparing full mass spectra with reference spectra.[21, 22, 23] 
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3.3 Aims of the Dissertation 
 
1. Identification of the phase I metabolites of MDPBP in rat urine using GC-MS. 
2. Confirmation of phase I and identification of phase II metabolites of MDPBP in rat 
urine using LC-MSn. 
3. Postulation of the metabolic pathways of MDPBP. 
4. Elucidation of the CYP isoenzymes involved in the main metabolic reactions. 
 
EXPERIMENTAL PROCEDURES/MATERIALS AND METHODS 
 
 
9 
 
4 EXPERIMENTAL PROCEDURES/MATERIALS AND METHODS 
 
4.1 Chemicals and Reagents 
 
MDPBP-HCl was provided by the Landeskriminalamt Schleswig-Holstein (Kiel, 
Germany) for research purposes. Isolute HCX cartridges (130 mg, 3 mL) were obtained 
from Biotage (Uppsala, Sweden), nicotinamide adenine dinucleotide phosphate 
(NADP+), Biomol (Hamburg, Germany) and isocitrate and isocitrate dehydrogenase 
from Sigma (Taufkirchen, Germany). Glucuronidase (EC No. 3.2.1.31) and arylsulfatase 
(EC No. 3.1.6.1) from Helix Pomatia L as well as all other chemicals and reagents were 
obtained from E. Merck (Darmstadt, Germany) and were of analytical grade. The 
following microsomes were from Gentest and delivered by NatuTec (Frankfurt/Main, 
Germany): baculovirus-infected insect cell microsomes (ICM) (Supersomes), containing 
1 nmol/ml of human cDNA-expressed CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1 (2 nmol/ml), CYP3A4, or CYP3A5 (2 nmol/ml) and 
pooled human liver microsomes (pHLM, 20 mg microsomal protein/ml, 420 pmol total 
CYP/mg protein). After delivery, the microsomes were thawed at 37°C, aliquoted, snap-
frozen in liquid nitrogen and stored at -80°C until use. 
 
 
4.2 Urine Samples 
 
Studies were accomplished using urine of male rats (Wistar, Charles River, Sulzfleck, 
Germany) for toxicological diagnostic reasons. They were administered a single 
20 mg/kg body mass dose of MDPBP for metabolism studies (identification of the 
metabolites) and a single of 1 mg/kg body mass dose for toxicological analysis 
(development of the screening procedure). The drug was applied in an aqueous 
suspension by gastric intubation. The rats were housed in metabolism cages for 24 h, 
having water ad libitum. Urine was collected separately from the feces over a 24 h 
period. All samples were directly analyzed and then stored at -20°C until further 
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analysis. Blank urine samples were collected before drug administration to check 
whether the samples were free of interfering compounds.  
 
 
4.3 Sample Preparation 
 
4.3.1 Sample preparation for the identification of the phase I metabolites by      
GC-MS 
 
A 2.5 mL portion of urine was adjusted to pH 5.2 with acetic acid (1 M, approximately 
50 µL) and incubated at 56°C for 1.5 h with a mixture (100 000 Fisherman u/mL) of 
glucuronidase and arylsulfatase. The urine samples were then diluted with 2.5 mL of 
water and loaded on solid phase extraction (SPE) Isolute HCX cartridges, previously 
conditioned with 1 mL of methanol and 1 mL of water. After passage of the sample, the 
cartridge was washed with 1 mL of water, 1 mL of 0.01 M hydrochloric acid and again 
with 1 mL of water. The retained non-basic compounds were first eluted into a 1.5 mL 
reaction vial with 1 mL of methanol (fraction 1), whereas the basic compounds were 
eluted in a second step into a different vial with 1 mL of a freshly prepared mixture of 
methanol/aqueous ammonia 32% (98:2 v/v; fraction 2). The eluates were gently 
evaporated to dryness under a stream of nitrogen at 56°C and then dissolved in 100 µL 
of methanol. Thereafter, the samples were divided into two aliquots and evaporated to 
dryness. One aliquot was dissolved in 50 µL methanol and one was derivatized 
according to published procedures for GC-MS.[23] Therefore, this aliquot was acetylated 
with 100 µL of acetic anhydride-pyridine mixture (3:2, v/v) for 5 min under microwave 
irradiation at about 440 W. After evaporation to dryness, the residue was dissolved in 
50 µL of methanol. A 1 µL aliquot was injected into the GC-MS system. 
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4.3.2 Sample preparation for the identification of the phase I and II metabolites by 
LC-MSn 
 
SPE as described in 4.3.1 without derivatization was used for the confirmation of phase 
I metabolites. For identification of phase II metabolites, 1 mL of the urine samples was 
loaded on a Confirm C18 cartridge. Prior to sample load, the column was conditioned 
with 1 mL of methanol and 3 mL of water. After passage of the sample, the cartridge 
was washed with 1 mL of water. The retained compounds were eluted into a 1.5 mL 
reaction vial with a mixture of 1 mL of methanol and 200 µL of acetone. The samples 
were then gently evaporated to dryness under a stream of nitrogen at 56°C and 
reconstituted in a mixture of 10 mM ammonium formate buffer and acetonitrile (1:1 v/v).  
 
 
4.4 Enzymatic Part 
 
4.4.1 Microsomal incubations 
 
In order to verify, which CYP isoenzymes are involved in the initial metabolic steps of 
MDPBP, microsomal incubations were performed at 37°C with 25 µM MDPBP with 
human liver microsomes (HLM), CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1, CYP3A4 or CYP3A5 for 30 min. Besides enzymes and 
substrate, incubation mixtures (final volume: 50 µL) consisted of 90 mM phosphate 
buffer (pH 7.4), 5 mM Mg2+, 5 mM isocitrate, 1.2 mM NADP+, 0.5 U/ml isocitrate 
dehydrogenase and 200 U/ml superoxide dismutase. Reactions were started by adding 
the ice-cold microsomes and stopped with 50 µl of an ice-cold mixture of acetonitrile 
and 0.1 µM internal standard diphenhydramine. The solution was centrifuged for 5 min 
at 14000 U/min. 60 µL of the supernatant was transferred to an autosampler vial and 
injected into LC-MSn system for analysis. LC-MSn conditions were chosen as described 
below.  
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4.4.2 Initial screening studies 
 
The initial screening studies with the ten most abundant human hepatic CYP´s were 
performed with 25 µM of MDPBP and 50 pmol/mL of CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, or CYP3A5 for 
30 min.  
 
 
4.4.3 Kinetic studies 
 
Determination of kinetic constants of the initial metabolic step, the demethylenation of 
MDPBP, was derived from incubations with an incubation time of 10 min and 
40 pmol/mL protein concentration for CYP2C19 and an incubation time of 30 min and 
40 pmol/mL of protein concentration in case of CYP2D6. The described incubation 
conditions (incubation time and protein concentration) were chosen to be within a linear 
range of metabolite formation. The following substrate concentrations were used as 
provided in Table 1. 
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Table 1: Substrate concentrations used for microsomal incubations [µM]. 
      
 
CYP2D6 
  
CYP2C19 
 
      
      
 
1 
  
1 
 
 
5 
  
5 
 
 
10 
  
10 
 
 
50 
  
50 
 
 
100 
  
100 
 
 
125 
  
125 
 
 
250 
  
250 
 
 
500 
  
500 
 
 
750 
  
750 
 
 
1000 
  
1000 
 
    
1500 
 
    
2000 
 
      
 
 
Enzyme kinetic constants were estimated by non-linear curve-fitting using GraphPad 
Prism 5.00 software (San Diego, CA). The Michaelis-Menten equation (Eqn. (1)) was 
used to calculate apparent Km values and Venzyme values for single-enzyme systems. 
 
 Venzyme = 
Vmax× [S] 
Km + [S] 
(1) 
 
Km is the substrate concentration at which the reaction rate is halfway maximal. 
Consequently, with the help of Km values it is possible to make a statement about the 
affinity of the particular P450s substrates. 
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4.4.4 Metabolite quantification 
 
Correct quantification of MDPBP-M (demethylenyl) in the incubation mixture was not 
possible, because there was no reference substance available. Instead, the peak area 
ratios of the respective target ions of MDPBP-M (demethylenyl) and its internal standard 
diphenhydramine were used.  
 
 
4.4.5 Calculation of relative activity factors, contributions and percentages of net 
clearance 
 
The relative activity factor (RAF) approach [24-26] was used to account for differences in 
functional levels of redox partners between the two enzyme sources. The turnover rates 
(TR) of CYP2C19 (probe substrate (PS) S-mephenytoin) and CYP2D6 (PS bufuralol) in 
insect cell microsomes (ICM) and human liver microsomes (HLM) were taken from the 
supplier's data sheets. The RAF´s were calculated according to equation (2). 
 
 
RAFenzyme = 
TRPS in HLM 
TRPS in ICM 
(2) 
    
The enzyme velocities Venzyme (see equation (1)) for the respective metabolic reactions 
were calculated and then multiplied with the corresponding RAF leading to a value, 
which is defined as 'contribution'. The Vmax and the Km values (equation (1)) were 
obtained from the incubations with complementary deoxyribonucleic acid (cDNA)-
expressed P450s. 
 
 contributionenzyme =   RAFenzyme × Venzyme (3) 
 
  
EXPERIMENTAL PROCEDURES/MATERIALS AND METHODS 
 
 
15 
 
From these corrected activities (contributions) the percentages of net clearance by a 
particular P450 can be calculated according to equation (4): 
 
 
clearanceenzyme [%] = 
contributionenzyme 
∑ contributionenzyme 
× 100 (4) 
 
 
 
4.5 GC-MS and LC-MSn Settings 
 
4.5.1 GC-MS apparatus  
 
The MDPBP metabolites were separated and analyzed in urine extracts using a Hewlett 
Packard (HP, Agilent, Waldbronn, Germany) 5890 Series II gas chromatograph 
combined with a HP 5972 MSD mass spectrometer and a HP MS ChemStation (DOS 
series) with HP G1034C software version C03.00. The GC conditions were as follows: 
splitless injection mode; column TG-1 MS Thermo Scientific (12 m × 0.2 mm ID), cross-
linked methyl silicone, 330 nm film thickness; injection port temperature, 280°C; carrier 
gas, helium; flow rate, 1 ml/min; column temperature, programmed from 100°C to 
310°C at 30°C/min, initial time 3 min, final time 8 min. The MS conditions were as 
follows: full-scan mode, m/z 50-550 u; electron ionization (EI) mode, ionization energy, 
70 eV; capillary direct interface, heated at 280°C, positive ion chemical ionization (PICI) 
mode using methane; ionization energy, 230 eV; ion source temperature, 220°C; 
capillary direct interface, heated at 260°C. 
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4.5.2 LC-MSn apparatus  
 
For metabolite identification, the LC-MSn gradient was programmed as described 
previously.[27, 28] MDPBP and their metabolites were analyzed using a ThermoFisher 
Scientific (TF, Dreieich, Germany) Accela LC system consisting of a degasser, a 
quaternary pump and a HTC PAL auto sampler (CTC Analytics AG, Zwingen, 
Switzerland), coupled to a TF Linear Ion Trap system equipped with a heated 
electrospray ionization II source. The LC conditions were as follows: TF Hypersil gold 
(10 x 2.1 mm, 1.9 µm), column temperature 35°C, and gradient elution with 10 mM 
aqueous ammonium formate buffer containing 0.1% (v/v) formic acid as mobile phase A 
and acetonitrile containing 0.1% (v/v) formic acid as mobile phase B. The flow rate was 
set to 0.5 mL/min and the gradient was programmed as follows: 0-1 min 98% A,           
1-3 min to 90% A, 3-5 min to 85% A, 5-7.5 min to 80% A, 7.5-10 min to 75% A,          
10-11.5 min to 65% A, 11.5-13 min to 65% A, 13-14.5 min to 50% A, 14.5 16 min to 
40% A, 16-19 min to 0% A, 19-21 min hold 0% A. Column flushing and equilibration 
were performed in additional methods with a methanol/water (85:15, v/v) solution. The 
MS conditions were as follows: heated electron spray ionization (HESI), positive mode, 
sheath gas, nitrogen at a flow rate of 41.5 arbitrary units (AU), auxiliary gas, nitrogen at 
a flow rate of 27.5 AU, vaporizer temperature 300°C, spray voltage 2.00 kV; ion transfer 
capillary temperature 380°C capillary voltage 16 V; tube lens voltage 75 V.  
Collision induced dissociation (CID)-MS/MS experiments were performed on precursor 
ions selected from MS1 using information-dependent acquisition (IDA): MS1 was 
performed in the full scan (FS) mode (m/z 100-800). MS2 and MS3 were performed in 
the CID mode: MS2 on the most intense signals from MS1; MS3 on the most and 
second most intense signals from MS2. Normalized collision energies were 35% and 
40% in MS2 and MS3, respectively. Other settings were as follows: minimum signal 
threshold: MS1: 100 counts, MS2: 50 counts, isolation width, 1.5 u; activation Q, 0.25; 
activation time, 30 ms; dynamic exclusion mode, repeat counts 2, repeat duration 15 s, 
exclusion list 50, exclusion duration 15 s. For kinetic studies, collision-induced 
dissociation (CID)-MSn experiments were performed on the following selected precursor 
ions from MS1 at m/z (u) 250, 256, 262, 276. The collision energies were the same as 
described before. For these studies, also the gradient was changed: 0-4 min from       
98% A to 60% A, 4-4.01 min to 10% A, hold to 7 min, 7.01 min back to 98% A and hold 
for 3 min. 
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5 RESULTS AND DISCUSSION 
 
5.1 Sample Preparation 
 
The cleavage of conjugates was necessary before the extraction and GC-MS analysis 
in order not to neglect completely conjugated phase I metabolites and gentle enzymatic 
hydrolysis was used instead of acid hydrolysis. Enzymatic hydrolysis at elevated 
temperature (56°C) and short time (1.5 h) was previously successfully applied.[2, 5-8, 29] 
Derivatization increased the sensitivity for detection of metabolites. In the present study 
acetylation was used in order to allow sensitive detection of possible primary or 
secondary amines and alcoholic and/or phenolic hydroxyl groups. This kind of 
derivatization has been provided to be useful in other metabolism studies and is favored 
for derivatization of metabolites with the above described chemical structures.[23, 30-32] 
 
 
5.2. Identification of the Phase I Metabolites by GC-MS 
 
The urinary metabolites of the substance MDPBP were identified by full-scan EI after 
GC separation.  
The postulated structures of the metabolites were deduced from the fragments detected 
in the EI mode, which were interpreted in correlation to those of the parent compound 
according to the fragmentation patterns of other pyrrolidinophenones[7, 8, 29] and the 
general fragmentation rules described by e.g. McLafferty and Turecek[21] and Smith and 
Busch.[33] In order to verify the molecular mass of the postulated metabolites, PICI mass 
spectra were recorded, but not shown in this study, because they contain strong 
molecular peaks (M+H+), in contrast to EI spectra. In addition, adduct ions typical for 
PICI with methane were produced (M+C2H5
+, M+C3H5
+). The gas chromatographic 
retention indices (RI) of the EI mass spectra were determined according to de-Zeeuw et 
al.[34] The EI mass spectra and the RI are shown in Fig. 3, the chemical structures and 
predominant fragmentation patterns of MDPBP and its metabolites in Fig. 4.  
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From the recorded mass spectra, the following metabolites (nos. in Fig. 3/4 are given in 
brackets) could be deduced from the acetylated and not acetylated urine extracts: 
MDPBP (1), MDPBP-M (deamino-oxo) (2), MDPBP-M (demethylenyl-methyl-deamino-
oxo) (3), MDPBP-M (demethylenyl-deamino-oxo) (4), MDPBP-M (demethylenyl-methyl-
deamino-oxo-dihydro) (5, 6), MDBPB-M (demethylenyl-deamino-oxo-dihydro) (7), 
MDPBP-M (demethylenyl-methyl-N,N-bis-dealkyl-HO-phenyl-dihydro) (10), MDPBP-M 
(demethylenyl-methyl-N,N-bis-dealkyl) (11), MDPBP-M (demethylenyl-methyl) (12, 13), 
MDPBP-M (pyrrolidinyl-oxo) (14), MDPBP-M (demethylenyl) (15), MDPBP-M 
(carboxy) (16), MDPBP-M (demethylenyl-methyl-pyrrolidinyl-oxo) (17), MDPBP-M 
(demethylenyl-methyl-HO-alkyl) (18, 20), MDPBP-M (demethylenyl-methyl-HO-
phenyl) (19), MDPBP-M (HO-alkyl) (21), MDPBP-M (carboxy-oxo) (22) and MDPBP-M 
(demethylenyl-methyl-carboxy-oxo) (23). Metabolites nos. 5 and 6, 12 and 13, 18 and 
20 were detected as diastereomers. The metabolite with the greatest abundance was 
supposed to be the 3´methylated compound (12) predicated on the assumption that the 
hydroxyl group at position 3´ was preferentially methylated by catechol-o-
methyltransferase (COMT) as already described for related substances.[35] 
Furthermore, the following artifacts were detected: MDPBP-M (demethylenyl-methyl-
oxo) artifact (-4H) (8), MDPBP-M (demethylenyl-methyl) artifact (-4H) (9). This can be 
explained by the fact that the pyrrolidine ring could be twice oxidized, so that one or two 
double bounds were formed. Loss of two (artifact (-2H)) or four (artifact (-4H)) protons 
results in a decrease of the molecular mass of two or four units and corresponding ions. 
PICI mass spectra with respective protonated molecular ions at acceptable abundance 
and the typical adduct ions could be detected for all metabolites excepting MDPBP-M 
(demethylenyl-deamino-oxo-dihydro) (7), MDPBP-M (demethylenyl-cmethyl-N,N-bis-
dealkyl-HO-phenyl-dihydro) (10) and MDPBP-M (carboxy) (16). This could be explained 
by the fact that these metabolites were formed to minor dimension not sufficient for 
detection in PICI mode. 
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Figure 3: EI mass spectra and gas chromatographic retention indices (RI) of MDPBP 
and its phase I metabolites arranged according to their RI. 
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Figure 3: continued 
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Figure 3: continued 
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Figure 3: continued 
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Figure 3: continued 
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Figure 4: Proposed structures and predominant fragmentation patterns of MDPBP and 
its phase I metabolites. 
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Figure 4: continued 
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5.3 Proposed Fragmentation Patterns for the Identification of the Phase I 
Metabolites by GC-MS 
 
In the following, important fragmentation patterns of the EI mass spectra of MDPBP and 
its derivatized metabolites will be discussed in relation to the postulated metabolite 
structures depicted in Fig. 3 and Fig. 4. The numbers of the corresponding mass 
spectra in Fig. 3 and Fig. 4 are given in brackets. 
The EI spectra showed comparable fragmentation characteristics like other alpha-
pyrrolidinophenones.[7-9] Furthermore, the EI spectrum of the underivatized MDPBP was 
identical with the spectrum recorded by Westphal et al. (mass spectrum no. 1 in        
Fig. 3).[10] 
The following fragmentation patterns could be observed (Fig. 5): alpha-cleavage 
between position one and two resulted in an ammonium ion with characteristic fragment 
ions at m/z 112 representing the base peak of the spectrum. Alternative alpha-cleavage 
between position one and two yielded to characteristic fragment ions at m/z 149, which 
are stabilized by mesomerism of the phenyl ring and the carbonyl moiety. A following 
CO loss led to characteristic fragment ions at ion m/z 121. The appearance of the 
fragment ions m/z 149 and m/z 121 in a mass chromatogram are indicating the 
presence of a methylenedioxybenzoyl moiety of the parent compound. Another alpha-
cleavage reaction between position two and three yielded a methylenedioxybenzoyl-
methylpyrrolidinyl cation with characteristic fragment ions at m/z 232. The pyrrolidine 
ring is represented by the fragment ions at m/z 70. 
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Figure 5: Characteristic EI fragmentation patterns of MDPBP. 
 
In analogy to the parent compound, for all derivatized metabolites, an alpha-cleavage 
between position one and two could be noticed leading to characteristic fragment ions 
at m/z 112 (1, 12, 13, 15, 19), m/z 126 (14, 17), m/z 58 (2, 3, 4, 5, 6, 7), m/z 170 (18, 
20, 21), m/z 200 (22, 23) or m/z 100 (10, 11). Alternative alpha-cleavage between 
position one and two yielded the following characteristic fragment ions at: m/z 149 (1, 2, 
14, 16, 21, 22), m/z 137 (4, 15), m/z 151 (3, 11, 12, 13, 17, 18, 20, 23), m/z 153 (5, 6), 
m/z 139 (7) and m/z 167 (19). For acetylated metabolites, a shift of 42 u, 84 u (twice 
acetylated) or 126 u (triple acetylated) was observed.  
The main metabolic steps are demethylenation of the methylenedioxybenzoyl moiety to 
the dihydroxy-metabolites followed by methylation. In analogy to the parent compound, 
an alpha cleavage between position one and two and a subsequent CO loss was 
observed in both derivatized metabolites (Fig. 6).  
O
O
CH3
O
N
O
O
O
N
+
CH3
N
+
O
O
C
+
O
C
+O
O
+
Spectrum no. 1 in Fig. 3
m/z 232
m/z 149m/z 112 m/z 121
MDPBP
RESULTS AND DISCUSSION 
 
 
28 
 
OH
OH
CH3
O
N
OH
OH
O
N
+
CH3
N
+
OH
OH
C
+
O
C
+OH
OH
+
O
OH
CH3
O
N
CH3
O
OH
O
N
+
CH3
CH3
N
+ O
OH
C
+
O
CH3 C
+O
OH
CH3
+
Spectrum no. 15 in Fig. 3
m/z 220
m/z 137m/z 112 m/z 109
MDPBP-M (demethylenyl)
Spectrum nos. 12, 13 in Fig. 3
m/z 234
m/z 151m/z 112 m/z 123
MDPBP-M (demethylenyl-methyl)
 
Figure 6: Characteristic EI fragmentation patterns of demethylenyl MDPBP (upper part) 
and demethylenyl-methyl MDPBP (lower part). 
 
Demethylenation led to the metabolite MDPBP-M (demethylenyl) (mass spectrum no.15 
in Fig. 3) with characteristic fragment ions at m/z 137 (alpha–cleavage) and 
characteristic fragment ions at m/z 109 (CO loss). Demethylenation and afterwards 
methylation yielded to MDPBP-M (demethylenyl-methyl) (mass spectra nos. 12, 13 in 
Fig. 3), which led to characteristic fragment ions at ion m/z 151 (alpha-cleavage) and 
fragment ions at m/z 123 (CO loss). So, appearances of the respective couples of ions 
in a mass chromatogram are indicating these metabolic steps. Because of the unaltered 
pyrrolidine ring in both metabolites, fragment ions at m/z 112 were still representing the 
base peak of the spectra. Both in acetylated and in not acetylated spectra two isomers 
of MDPBP-M (demethylenyl-methyl) could be identified (12, 13). They yielded almost 
the same mass spectra, but have different RI´s. However, it is not possible to 
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determine, which diastereomer belongs to which spectrum only based on fragmentation 
patterns. It could be supposed, that the diastereomer with greater abundance was the 
3´-methylated, because former studies proved that this metabolic step is catalyzed by 
catechol-O-methyl transferase (COMT) leading to methylation of the hydroxyl groups in 
position 3´ preferentially.[8, 9]  
Both metabolites could be derivatized by acetylation (Fig. 7). Via alpha-cleavage 
between position one and two in the acetylated metabolites, the following characteristic 
fragment ions were formed: m/z 193 (12, 13) in case of the demethylenyl-methyl-
metabolites and m/z 221 in case of the demethylenyl-metabolites (15). Loss of acetyl 
moieties caused fragment ions at m/z 151 (12, 13), m/z 179 and m/z 137 (15). 
In dependence of the above described alpha-cleavage between position two and three 
in the acetylated metabolites the following fragment ions could be detected: at m/z 276 
(12, 13) and at m/z 304 (15). Loss of acetyl moieties led to fragment ions at m/z 234 
(12, 13) and at m/z 262 (15). 
The presence of fragment ions at m/z 276, 234, 193, and 151 indicates the acetylated 
type of MDPBP-M (demethylenyl-methyl) (12, 13) and the appearance of the fragment 
ions at m/z 304, 262, 221, 179 and 137 shows the twice acetylated type of MDPBP-M 
(demethylenyl) (15) (Fig. 7). 
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Figure 7: Characteristic EI fragmentation patterns of acetylated demethylenyl-methyl 
MDPBP (lower) and twice acetylated demethylenyl MDPBP (upper). 
 
Another metabolic step was the oxidation of the pyrrolidine part or the butyl chain. The 
oxidation of the butyl-pyrrolidine moiety was represented by ions formed after alpha-
cleavage between position one and two: fragment ions at m/z 126 (14, 17) for oxidation 
of the pyrrolidine part, which is depicted by a shift of 14 u (from fragment ions at        
m/z 112 to fragment ions at m/z 126), and fragment ions at m/z 170 (18, 20, 21) or 
fragment ions at m/z 200 (22, 23) for oxidation of the butyl chain. Subsequently, a 
neutral loss of acetic acid corresponding to 60 u led to fragment ions at m/z 110 (18, 20, 
21). In case of oxidation of the pyrrolidine ring fragment ions at m/z 126 were 
representing the base peak of the mass spectra.  
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However, it must be mentioned that the exact position of the oxo group in pyrrolidinyl-
oxo-metabolites could not be identified from the fragmentation patterns. In dependence 
on studies on the metabolism of other pyrrolidinophenones, the carbon atom was 
oxidized in position 2´ to lactam rather than in other positions, e.g. prolintane and 
nicotine are known for this.[2, 3, 5, 36-38] 
From these data it could be deduced that metabolites 12, 13, 15 and 19 in Fig. 3 
remained unchanged at the butyl-pyrrolidine moiety, which was in agreement with their 
spectra. 
Further metabolic steps leading to carboxy-metabolites are the following: hydroxylation 
of the 2´-position of the pyrrolidine ring followed by ring opening to the respective 
aliphatic aldehyde that is further oxidized to the carboxylic acid (16, 22, 23) and finally 
degradation to primary amines (10, 11). These assumptions are in accordance with a 
similar metabolic pathway of phencyclidine or PVP, which was described by 
Holsztynska et al. and by Sauer et al.[8, 39] This perception approves again that the oxo 
group of the pyrrolidinyl-oxo-metabolites was indeed in position 2´, because such 
carboxy-metabolites could only be in the run if hydroxylation took place at this position. 
In case of carboxy-pyrrolidinyl-oxo-metabolites (22, 23), fragmentation was different 
from previously described ones. Alpha-cleavage between position one and two now 
resulted in the fragment ions at m/z 200 (22, 23). A shift of 42 u led to fragment ions at 
m/z 158, which implies a neutral loss of an acetyl group. This fragmentation suggested 
a ring opening of the pyrrolidine moiety leading to a carboxylic acid. After degradation to 
primary amine alpha-cleavage between position one and two yielded to fragment ions at 
m/z 100 (10, 11). A neutral loss of an acetyl group (shift of 42 u) led to the fragment ions 
at m/z 58. Similar metabolic steps were previously described for PVP and MDPPP.[8, 9]  
Structurally related substances such as cathinones[40] are known for their dihydro-
metabolites, which are additionally excreted in human beings to a remarkable extent. 
Such metabolites could also be detected in GC-MS analysis of MDPBP (5, 6, 7, 10). As 
only acetylated dihydro-metabolites could be observed, alpha-cleavage between 
position one and two led to fragment ions, which were shifted to 44 u, because of 
reduction of the keto compound to the secondary alcohol (2 u) and subsequent 
acetylation (42 u).  
Oxidative deamination led to corresponding 2´-oxo compounds (2, 3, 4, 5, 6, 7). 
Because of losing pyrrolidine ring, alpha-cleavage between position one and two 
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resulted in fragment ions at m/z 58. Acetylation of these metabolites was not possible. 
Characteristically for these metabolites was the loss of basic compounds with the 
consequence that there was no more nitrogen for ionization. Therefore, these 
metabolites could only be detected by GC-MS, but not by LC-MSn. 
Other detected metabolites were formed by hydroxylation of the butyl chain or benzene 
ring. Based on the different fragmentation patterns, the detected hydroxyl-metabolites 
could be separated. Alpha-cleavage between position one and two of the acetylated 
HO-alkyl led to fragment ions at m/z 170 (18, 20, 21). A neutral loss of an acetic acid 
moiety yielded to fragment ions at m/z 110 (60 u shift). But the position of the hydroxyl 
group in the butyl side chain could not be exactly identified by fragmentation patterns. 
Similar problems had previously been described for other pyrrolidinophenones.[29] It was 
shown that short alkyl chains are most likely hydroxylated in position ω-1 at the 
penultimate carbon atom.[8] No acetylated HO-alkyl-metabolites could be found. Alpha 
cleavage between position one and two resulted in fragment ions at m/z 128, which 
were representing the base peak of the mass spectrum. Phenolic hydroxylation could 
also be detected (19). Alpha-cleavage between position one and two of the acetylated 
phenolic-metabolites resulted in the described fragment ions at m/z 112, which 
represented the base peak of the spectrum. Alternative alpha-cleavage at this position 
yielded to other fragmentation patterns than previously discussed. The following 
fragment ions were detected: at m/z 251, 209 and 167, which could be explained by 
loss of two acetyl moieties (42 u shift). Consequently, appearance of the respective ions 
allowed differentiation of HO-alkyl- and HO-phenyl-metabolites. 
Moreover, the following artifacts were detected: MDPBP-M (demethylenyl-methyl) 
artifact (-4H) (9) and MDPBP-M (demethylenyl-methyl-oxo) artifact (-4H) (8). Alpha-
cleavage between position one and two on the (-4H) artifacts led to fragment ions at  
m/z 108, which depicted the base peak of the spectrum (9). This phenomenon could be 
explained by building two double bounds into pyrrolidine ring, which resulted in a loss of 
four protons and causes the above described ion change of fragment ions at m/z 112 to 
fragment ions at m/z 108. Via the (-4H) artifact of MDPBP-M (demethylenyl-methyl-
pyrrolidinyl-oxo) an oxo compound could be detected (8). Here, the oxo group could 
only be located at the butyl side chain and not at the pyrrolidine ring, because there was 
no more space for another compound.  
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5.4 Identification of the Phase II Metabolites by LC-MSn 
 
Glucuronides or sulfates were identified using LC-MSn. The formation of the phase II 
metabolites could be confirmed by comparing the corresponding MSn spectra of the 
phase II metabolites with the MSn-1 spectra of the phase I metabolites. 
Using this approach, the following phase II metabolites (summarized also in Table 2) 
could be identified in rat urine (the numbers given in brackets correspond to those in 
Table 2): MDPBP-M (demethylenyl-glucuronide) (1, 2), MDPBP-M (demethylenyl-
sulfate) (3), MDPBP-M (demethylenyl-methyl-pyrrolidinyl-oxo-glucuronide) (4),   
MDPBP-M (demethylenyl-methyl-glucuronide) (5, 6), MDPBP-M (demethylenyl-
pyrrolidinyl-oxo-glucuronide) (7, 8), MDPBP-M (demethylenyl-methyl-HO-phenyl-
glucuronide) (9, 10) and MDPBP-M (demethylenyl-methyl-HO-alkyl-glucuronide) (11). 
Compound 1 and 2, 5 and 6, 7 and 8, 9 and 10 could be detected as diastereomers. 
However, the position of the glucuronic acid could not be exactly determined from 
fragmentation patterns and in case of diastereomers it was not possible to make a 
decision, which spectrum belongs to which diastereomer.  
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Table 2: Phase II metabolites of MDPBP with fragment ions of their MS1, MS2 and 
MS3 spectra and their nominal masses using LC-MSn.  
 
 
  
Metabolite MS nominal mass
1 MDPBP-M (demethylenyl-glucuronide) isomer-1 MS1 426
MS2 on 426 161, 179, 250
MS3 on 250 72, 112, 123, 151, 161, 179, 250
MS3 on 179 123, 133, 151
2 MDPBP-M (demethylenyl-glucuronide) isomer-2 MS1 426
MS2 on 426 161, 179, 250
MS3 on 250 72, 112, 123, 151, 161, 179, 250
MS3 on 179 105, 123, 133, 151
3 MDPBP-M (demethylenyl-sulfate) MS1 330
MS2 on 330 179, 250
MS3 on 250 72, 112, 123, 151, 161, 179, 250
MS3 on 179 123, 151
4 MDPBP-M (demethylenyl-methyl-pyrrolidinyl-oxo-glucuronide) MS1 454
MS2 on 454 154, 278
MS3 on 278 98, 126, 154, 193
MS3 on 154 126
5 MDPBP-M (demethylenyl-methyl-glucuronide) isomer-1 MS1 440
MS2 on 440 161, 193, 264
MS3 on 264 112, 151, 161, 193, 264
MS3 on 161 103, 133
6 MDPBP-M (demethylenyl-methyl-glucuronide) isomer-2 MS1 440
MS2 on 440 161, 193, 264
MS3 on 264 112, 151, 161, 193, 264
MS3 on 193 161
7 MDPBP-M (demethylenyl-pyrrolidinyl-oxo-glucuronide) isomer-1 MS1 440
MS2 on 440 126, 208, 264
MS3 on 264 98, 126, 137, 154, 179, 264
MS3 on 126 82, 98
8 MDPBP-M (demethylenyl-pyrrolidinyl-oxo-glucuronide) isomer-2 MS1 440
MS2 on 440 126, 154, 264
MS3 on 264 98, 126, 137, 154, 179, 264
MS3 on 126 98
9 MDPBP-M (demethylenyl-methyl-HO-phenyl-glucuronide) isomer-1 MS1 456
MS2 on 456 177, 209, 280
MS3 on 280 112, 149, 167, 177, 209
MS3 on 209 149, 177
10 MDPBP-M (demethylenyl-methyl-HO-phenyl-glucuronide) isomer-2 MS1 456
MS2 on 456 177, 209, 280
MS3 on 280 112, 149, 167, 177, 209
MS3 on 209 177
11 MDPBP-M (demethylenyl-methyl-HO-alkyl-glucuronide) MS1 456
MS2 on 456 128, 177, 209, 280
MS3 on 280 112, 128, 149, 161, 177, 209
MS3 on 209 149, 177
RESULTS AND DISCUSSION 
 
 
35 
 
5.5 Proposed Metabolic Pathways 
 
By means of the identified and above described metabolites of MDPBP, the following 
partly overlapping pathways could be postulated (numbers in brackets correspond to 
those used in Fig. 3 and Fig. 4): Demethylenation of the methylenedioxy group (4, 7, 
15), following by methylation of the dihydroxy-metabolites, most probably by COMT, to 
the corresponding demethylenyl-methyl compounds (3, 5, 6, 10, 11, 12, 13, 17, 18, 19, 
20, 23), oxidative deamination to the corresponding 2´-oxo compounds (2, 3, 4, 5, 6, 7), 
hydroxylation of the butyl side chain (18, 20, 21) and oxidation to the corresponding 
ketones (22, 23), hydroxylation of the phenyl ring (10, 19), hydroxylation of the            
2´-position of the pyrrolidine ring followed by dehydrogenation to the corresponding 
lactams (14, 17), hydroxylation of the 2´-position of the pyrrolidine ring followed by ring 
opening to the respective aliphatic aldehyde and further oxidation to the carboxylic acids 
(16, 22, 23), degradation of the pyrrolidine ring to the corresponding primary amines 
(10, 11) and reduction of the keto group to the corresponding secondary alcohols (5, 6, 
7, 10). Metabolites 12, 13, 15, 17, 18, 19 and 20 were partly excreted as glucuronides 
and/or sulfates. 
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Figure 8: Proposed scheme for metabolism of MDPBP in rats. The numbering of the 
compounds corresponds to that of the mass spectra of the corresponding        
compound in Fig. 3. 
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5.6 Enzymatic Part 
 
5.6.1 Initial CYP screening 
 
The initial screening studies with the ten most abundant human hepatic CYP´s were 
used to identify their ability for catalyzing the formation of the initial metabolite,   
MDPBP-M (demethylenyl), in vitro. According to the supplier´s advice, the incubation 
conditions chosen were adequate to make a statement about the general involvement 
of a particular CYP enzyme. As shown in Fig. 9, the following CYP´s were in general 
capable to catalyze the demethylenation of MDPBP: CYP1A2, CYP2B6, CYP2C19, 
CYP2D6, CYP3A4 and CYP3A5. 
 
 
Figure 9: Metabolite formation (A/IS) of MDPBP-M (demethylenyl) formed after 
incubation of 25 µM substrate (37°C, 30 min) using human liver microsomes (50 mg 
protein/mL) and the ten most important recombinant CYP isoenzymes as enzyme 
source. Data are the average of two determinations. 
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5.6.2 Kinetic studies 
 
The kinetic parameters were determined for the two most abundant CYP´s, which 
catalyze the demethylenation of MDPBP. The Km values, which are representing the in 
vitro affinity of the particular P450s substrates and the Vmax values are listed in Table 3. 
Both kinetic profiles fit well into Michaelis-Menten kinetics. In case of CYP1A2, 
CYP2B6, CYP3A4, and CYP3A5 activities were too low for calculation of kinetic 
parameters.  
 
Table 3: Calculated Km values (µM) and Vmax values (au). 
Enzyme 
Km for MDPBP-M 
(demethylenyl) formation 
Km for MDPBP-M 
(demethylenyl) formation 
      
CYP2D6 12 4.25 
      
CYP2C19 194 2 
      
 
The net clearances for particular P450s at the four substance concentrations 0.1 µM,    
1 µM, 10 µM and 100 µM were calculated to be 95%, 92%, 76% or 61% for CYP2D6 
and 5%, 8%, 24% or 39% for CYP2C19. In conclusion, the net clearance data indicated 
that CYP2D6 was responsible for the main part of the total MDPBP CYP-dependent 
clearance and CYP2C19 is becoming more important at higher substrate 
concentrations. 
 
 
5.6.3 Possible CYP interactions 
 
Concerning the above described kinetic studies CYP2D6 and CYP2C19 turned out to 
be responsible for the initial metabolism step: the demethylenation of MDPBP. This is in 
accordance with previously published data of other pyrrolidinophenones with 
demethylenation as initial step like MDPV.[9] Therefore, it should be taken into account, 
that interactions might be possible between CYP2D6 or CYP2C19 and inhibitors of 
these enzymes, for example quinidine or 3´,4´-methylenedioxy-methamphetamine 
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(MDMA) (inhibitor of CYP2D6)[9, 41, 42] or fluconazole (inhibitor of CYP2C19).[9, 42] A 
common intake of such an inhibitor with MDPBP would lead to increased plasma 
concentrations and consequently increased adverse reactions. Additionally, genetic 
polymorphisms have to be taken into account and then have to be considered while 
interpreting plasma concentrations of the designer drug. CYP2D6 shows the largest 
variability in genetic polymorphism. This genetic basis of variability leads to different 
CYP2D6 functions: normal, reduced and non-existent, which causes a wide range from 
poor to ultra-rapid metabolizers.[43, 44] 
Furthermore, inhibition studies are necessary to elucidate the inhibition potential of 
MDPBP. It was shown, that for example MDPV or MDMA, which are metabolized to a 
catechol by CYP2D6, are mechanism based inhibitors of CYP1A2 and CYP2D6.[9, 41] 
However, this question should be target of further studies. 
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6 CONCLUSIONS 
 
The presented study about the new designer drug MDPBP demonstrates that this new 
drug was extensively metabolized by rats. Assuming similar kinetics between rats and 
humans, drug screening approaches should be focused on the metabolites and not on 
the parent compound. The metabolites showed similar fragmentation patterns than 
previous studies on alpha-pyrrolidinophenones. Both, GC-MS and LC-MSn could be 
used for identifying phase I metabolites but GC-MS yielded better results and more 
metabolites could be found. Different CYP isoenzymes were found to be involved in the 
metabolism of MDPBP and these conclusions are in accordance with the results of 
other alpha-pyrrolidinophenone enzymatic studies. 
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8 ABBREVIATIONS 
 
AU  Arbitrary Units 
cDNA  Complementary Deoxyribonucleic Acid 
CID  Collision Induced Dissociation 
COMT Catechol-o-methyltransferase 
CYP  Cytochrome P450 
EI  Electron Ionization 
FS  Full Scan 
GC  Gas Chromatography 
HCl  Hydrochloride 
HESI  Heated Electron Spray Ionization 
HLM  Human Liver Microsomes 
HP  Hewlett Packard 
HR   High Resolution 
ICM  Insect Cell Microsomes 
IS  Internal Standard 
LC  Liquid Chromatography 
LD50  Median Lethal Lose 
MDPBP 3´,4´-methylenedioxy-alpha-pyrrolidinobutyrophenone 
MDPPP 3´,4´-methylenedioxy-alpha-pyrrolidinopropiophenone 
MDPV Methylenedioxy-pyrovalerone 
MDMA 3´,4´-methylenedioxy-methamphetamine 
MOPPP 4´-methoxy-alpha-pyrrolidinopropiophenone 
MPBP  4´-methyl-alpha-pyrrolidinobutyrophenone 
MPHP 4´-methyl-alpha-pyrrolidinohexanophenone 
ABBREVIATIONS 
 
 
45 
 
MPPP  4´-methyl-alpha-pyrrolidinopropiophenone 
MS   Mass Spectrometry 
NADP+ Nicotinamide Adenine Dinucleotide Phosphate 
NRG-1 Energy-1 
pHLM  Pooled Human Liver Microsomes 
PICI  Positive Ion Chemical Ionization 
PPP  Alpha-pyrrolidinopropiophenone 
PS  Probe Substrate 
PVP  Alpha-pyrrolidinovalerophenone 
RAF  Relative Aactivity Factor 
RI  Retention Index 
SPE  Solide Phase Extraction 
TR  Turnover Rate 
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